🕒 Last update: loading…

Stock Big Pharma Split Corp. PRM.TO

Big Pharma Split Corp. — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 13.49%

Price change 2019 → 2020: -4.63%

Price change 2020 → 2021: 9.48%

Price change 2021 → 2022: -0.61%

Price change 2022 → 2023: -5.69%

Price change 2023 → 2024: -5.38%

Price change 2024 → 2025: 6.92%

Price change 2025 → 2026: 6.25%

Price change 2026 (year to date): 9.32%

Financial growth

Revenue CAGR (8 years): -10.79%

Earnings CAGR (8 years): 6.78%

Growth status: positive trend (>1%/yr) in revenue OR earnings, but not both.

Debt

Debt-to-equity ratio: 0.72

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -25.83

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 4.65% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Big Pharma Split Corp.–0.72+17.2 %🔒
Netcapital Inc.–0.18+60.8 %–
Big Banc Split Corp.6.30.59+1.8 %–
HG Holdings, Inc.9.40.01−13.6 %–
Innventure, Inc.–0.16+2.6 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Big Pharma Split Corp. over the latest fiscal years.

Revenue
1.0 m USD
fiscal year 2025
Net income
3.1 m USD
fiscal year 2025
Net margin
302.7 %
fiscal year 2025
Average annual growth
-13.9 %
Revenue growth over 5 years
Market cap
14.7 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20202.2 m186,0068.6 %n/a
20213.8 m3.4 m90.6 %+74.0 %
20222.8 m2.2 m80.1 %-26.7 %
2023218,481-97,886-44.8 %-92.1 %
20241.3 m-377,462-29.1 %+493.1 %
20251.0 m3.1 m302.7 %-21.4 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Toronto Stock Exchange
IPO: 27/11/2017
ISIN code
CA08934P1080
Chief executive
Louis Michael Kovacs

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Big Pharma Split Corp.

What is the Big Pharma Split Corp. share price?

Latest recorded price: 16.02 CAD on 13/11/2026, for a market cap of 14.7 m USD.

What is the revenue of Big Pharma Split Corp.?

1.0 m USD for fiscal year 2025, with net income of 3.1 m USD (net margin 302.7 %).

Is Big Pharma Split Corp. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN CA08934P1080).

Who runs Big Pharma Split Corp.?

Louis Michael Kovacs is the company's chief executive.

07

Similar stocks